Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
ConditionMajor Depressive Disorder
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-45
SponsorMclean Hospital
About this trial
This study looks at the role of the Nociceptin/Orphanin FQ receptor system in the brain of individuals with current or past major depressive disorder (MDD). It also examines how individuals with a history of depression make certain decisions and which brain regions are involved in such decisions. Information collected through MRI, PET, biospecimens (i.e., blood, saliva) and behavioral tasks will be used to predict depressive symptoms in the future.
Eligibility criteria
Qualifiers
All genders, races, and ethnic origins, aged between 18 and 45
Capable of providing written informed consent, and fluent in English
Right-handed
Absence of any psychotropic medications for at least 2 weeks
Disqualifiers
Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment
Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, or partner with vasectomy)
Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease
History of seizure disorder
Trial design
Treatments tested in this trial
- Aversive stimuli
- PET radiotracer
Treatment groups
228 Participants
are divided into 3 treatment groupsSponsors and collaborators
Mclean Hospital
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Source ClinicalTrials.gov